Login Register Cart 0
Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Recurrent Wheezing in a Child: Unraveling Atypical Presentations of Cystic Fibrosis and Polymorphisms: A Case Report

Author(s): Santiago Presti, Manuela Lo Bianco, Maria Papale*, Desiree Balconara, Monica Tosto, Laura Sciuto, Federico Mollica, Enza Mule, Donatella Aloisio and Novella Rotolo

Volume 20, Issue 4, 2024

Published on: 08 April, 2024

Page: [355 - 359] Pages: 5

DOI: 10.2174/011573398X284981240402060853

Price: $65

Abstract

Background: Cystic Fibrosis (CF), is the most common, life-limiting, single-gene disease affecting the Caucasian population, with a reported incidence of1/3500 births. It is inherited in an autosomal recessive fashion and its diagnosis is notably challenging, since in several cases CF may not be detected by the newborn screening test and the sweat test, which are frequently reported negative of with doubtful results, especially in cases with atypical symptoms at onset or with uncommon mutations or polymorphisms.

Case Presentation: In this case, we present a case of CF presented with recurrent wheezing, reporting multiple negative or borderline sweat tests. The genetic evaluation revealed delta F508 (CF- causing) and heterozygous poly T5 polymorphism TG11 (TG)11T5.

Conclusion: The importance of this case lies in the recognition of wheezing as a symptom and not as a disease, thus many conditions such as CF have to be considered in its diagnostic process. Finally, it is of utmost importance to bear in mind that many mutations or polymorphisms might evade newborn screening and sweat tests.

« Previous Next »
[1]
Turcios NL. Cystic fibrosis lung disease: An overview. Respir Care 2020; 65(2): 233-51.
[http://dx.doi.org/10.4187/respcare.06697] [PMID: 31772069]
[2]
Fisman D. Cystic fibrosis heterozygosity: Carrier state or haploinsufficiency? Proc Natl Acad Sci 2020; 117(6): 2740-2.
[http://dx.doi.org/10.1073/pnas.1921730117] [PMID: 31992636]
[3]
Stoltz DA, Meyerholz DK, Welsh MJ. Origins of cystic fibrosis lung disease. N Engl J Med 2015; 372(4): 351-62.
[http://dx.doi.org/10.1056/NEJMra1300109] [PMID: 25607428]
[4]
Parisi GF, Cutello S, Di Dio G, Rotolo N, La Rosa M, Leonardi S. Phenotypic expression of the p.Leu1077Pro CFTR mutation in sicilian cystic fibrosis patients. BMC Res Notes 2013; 6(1): 461.
[http://dx.doi.org/10.1186/1756-0500-6-461] [PMID: 24225052]
[5]
Spicuzza L, Parisi GF, Tardino L, et al. Exhaled markers of antioxidant activity and oxidative stress in stable cystic fibrosis patients with moderate lung disease. J Breath Res 2018; 12(2): 026010.
[http://dx.doi.org/10.1088/1752-7163/aa9b39] [PMID: 29146889]
[6]
Parisi GF, Papale M, Rotolo N, et al. Severe disease in cystic fibrosis and fecal calprotectin levels. Immunobiology 2017; 222(3): 582-6.
[http://dx.doi.org/10.1016/j.imbio.2016.11.005] [PMID: 28012584]
[7]
Leonardi S, Parisi GF, Capizzi A, et al. YKL-40 as marker of severe lung disease in cystic fibrosis patients. J Cyst Fibros 2016; 15(5): 583-6.
[http://dx.doi.org/10.1016/j.jcf.2015.12.020] [PMID: 26778616]
[8]
Dickinson KM, Collaco JM. Cystic fibrosis. Pediatr Rev 2021; 42(2): 55-67.
[http://dx.doi.org/10.1542/pir.2019-0212] [PMID: 33526571]
[9]
Bergeron C, Cantin AM. Cystic fibrosis: Pathophysiology of lung disease. Semin Respir Crit Care Med 2019; 40(6): 715-26.
[http://dx.doi.org/10.1055/s-0039-1694021] [PMID: 31659725]
[10]
De Boeck K, Vermeulen F, Dupont L. The diagnosis of cystic fibrosis. Presse Med 2017; 46(6 Pt 2): e97-e108.
[http://dx.doi.org/10.1016/j.lpm.2017.04.010]
[11]
Pagin A, Gaudelus SI, Burgel PR. Genetic diagnosis in practice: From cystic fibrosis to CFTR-related disorders. Arch Pediatr 2020; 27(S1): eS25-9.
[http://dx.doi.org/10.1016/S0929-693X(20)30047-6] [PMID: 32172933]
[12]
Michl RK, Tabori H, Hentschel J, Beck JF, Mainz JG. Clinical approach to the diagnosis and treatment of cystic fibrosis and CFTR-related disorders. Expert Rev Respir Med 2016; 10(11): 1177-86.
[http://dx.doi.org/10.1080/17476348.2016.1240032] [PMID: 27653767]
[13]
Bombieri C, Claustres M, De Boeck K, et al. Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros 2011; 10(S2): S86-S102.
[http://dx.doi.org/10.1016/S1569-1993(11)60014-3] [PMID: 21658649]
[14]
Manti S, Licari A. How to obtain informed consent for research. Breathe 2018; 14(2): 145-52.
[http://dx.doi.org/10.1183/20734735.001918] [PMID: 29875834]
[15]
Parisi GF, Manti S, Papale M, et al. Addition of a nutraceutical to montelukast or inhaled steroid in the treatment of wheezing during COVID-19 pandemic: A multicenter, open-label, randomized controlled trial. Acta Biomed 2022; 93(2): e2022156.
[http://dx.doi.org/10.23750/abm.v93i2.11958-] [PMID: 35546018]
[16]
Manti S, Licari A, Leonardi S, Marseglia GL. Management of asthma exacerbations in the paediatric population: A systematic review. Eur Respir Rev 2021; 30(161): 200367.
[http://dx.doi.org/10.1183/16000617.0367-2020] [PMID: 34261742]
[17]
de Faria Poloni J, Rispoli T, Rossetti ML, Trindade C, Vargas JE. Cystic fibrosis: Systems biology analysis from homozygous p.Phe508del variant patients’ samples reveals perturbations in tissue-specific pathways. BioMed Res Int 2021; 2021: 1-16.
[http://dx.doi.org/10.1155/2021/5262000] [PMID: 34901273]
[18]
Castellani C, Cuppens H, Macek M Jr, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 2008; 7(3): 179-96.
[http://dx.doi.org/10.1016/j.jcf.2008.03.009] [PMID: 18456578]
[19]
Huang Q, Ding W, Wei MX. Comparative analysis of common CFTR polymorphisms poly-T, TG-repeats and M470V in a healthy Chinese population. World J Gastroenterol 2008; 14(12): 1925-30.
[http://dx.doi.org/10.3748/wjg.14.1925] [PMID: 18350634]
[20]
Niksic M, Romano M, Buratti E, Pagani F, Baralle FE. Functional analysis of cis-acting elements regulating the alternative splicing of human CFTR exon 9. Hum Mol Genet 1999; 8(13): 2339-49.
[http://dx.doi.org/10.1093/hmg/8.13.2339] [PMID: 10556281]
[21]
Chin S, Ranieri E, Gerace RL, Nelson PV, Carey WF. Frequency of intron 8 CFTR polythymidine sequence variant in neonatal blood specimens. Lancet 1997; 350(9088): 1368-9.
[http://dx.doi.org/10.1016/S0140-6736(05)65140-9] [PMID: 9365460]
[22]
Groman JD, Hefferon TW, Casals T, et al. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet 2004; 74(1): 176-9.
[http://dx.doi.org/10.1086/381001] [PMID: 14685937]
[23]
Chiang HS, Lu JF, Liu CH, Wu YN, Wu CC. CFTR (TG)m(T)n polymorphism in patients with CBAVD in a population expressing low incidence of cystic fibrosis. Clin Genet 2009; 76(3): 282-6.
[http://dx.doi.org/10.1111/j.1399-0004.2009.01258.x] [PMID: 19737283]
[24]
Grangeia A, Niel F, Carvalho F, et al. Characterization of cystic fibrosis conductance transmembrane regulator gene mutations and IVS8 poly(T) variants in Portuguese patients with congenital absence of the vas deferens. Hum Reprod 2004; 19(11): 2502-8.
[http://dx.doi.org/10.1093/humrep/deh462] [PMID: 15333598]
[25]
Huber KR, Mirkovic B, Nersesian R, Myers A, Saiki R, Bauer K. Survey of CF mutations in the clinical laboratory. BMC Clin Pathol 2002; 2(1): 4.
[http://dx.doi.org/10.1186/1472-6890-2-4] [PMID: 12437773]
[26]
Tabaripour R, Niaki HA, Douki MRE, Bazzaz JT, Larijani B, Yaghmaei P. Poly thymidine polymorphism and cystic fibrosis in a non-Caucasian population. Dis Markers 2012; 32(4): 241-6.
[http://dx.doi.org/10.1155/2012/910729] [PMID: 22430190]
[27]
Radpour R, Gilani MAS, Gourabi H, Dizaj AV, Mollamohamadi S. Molecular analysis of the IVS8-T splice variant 5T and M470V exon 10 missense polymorphism in Iranian males with congenital bilateral absence of the vas deferens. Mol Hum Reprod 2006; 12(7): 469-73.
[http://dx.doi.org/10.1093/molehr/gal046] [PMID: 16714368]
[28]
Ni WH, Jiang L, Fei QJ, Jin JY, Yang X, Huang XF. The CFTR polymorphisms poly-T, TG-repeats and M470V in Chinese males with congenital bilateral absence of the vas deferens. Asian J Androl 2012; 14(5): 687-90.
[http://dx.doi.org/10.1038/aja.2012.43] [PMID: 22842702]
[29]
Gaikwad A, Khan S, Kadam S, et al. The CFTR gene mild variants poly-T, TG repeats and M470V detection in Indian men with congenital bilateral absence of vas deferens. Andrologia 2018; 50(2): e12858.
[http://dx.doi.org/10.1111/and.12858] [PMID: 28776713]
[30]
Du Q, Li Z, Pan Y, Liu X, Pan B, Wu B. The CFTR M470V, intron 8 poly-T, and 8 TG-repeats detection in Chinese males with congenital bilateral absence of the vas deferens. BioMed Res Int 2014; 2014: 1-7.
[http://dx.doi.org/10.1155/2014/689185] [PMID: 24551851]
[31]
Radosavljevic I, Stojanovic B, Spasic M, Jankovic S, Djordjevic N. CFTR IVS8 poly-T variation affects severity of acute pancreatitis in women. J Gastrointest Surg 2019; 23(5): 975-81.
[http://dx.doi.org/10.1007/s11605-018-3913-8] [PMID: 30132293]
[32]
Aoyagi H, Okada T, Hasatani K, et al. Impact of cystic fibrosis transmembrane conductance regulator gene mutation on the occurrence of chronic pancreatitis in Japanese patients. J Int Med Res 2009; 37(2): 378-84.
[http://dx.doi.org/10.1177/147323000903700212] [PMID: 19383231]
[33]
Manti S, Parisi GF, Papale M, Marseglia GL, Licari A, Leonardi S. Type 2 inflammation in cystic fibrosis: New insights. Pediatr Allergy Immunol 2022; 33(S27): 15-7.
[http://dx.doi.org/10.1111/pai.13619] [PMID: 35080292]
[34]
Chirico V, Lacquaniti A, Leonardi S, et al. Acute pulmonary exacerbation and lung function decline in patients with cystic fibrosis: High-mobility group box 1 (HMGB1) between inflammation and infection. Clin Microbiol Infect 2015; 21(4): 368.e1-9.
[http://dx.doi.org/10.1016/j.cmi.2014.11.004] [PMID: 25658530]
[35]
Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002; 109(5): 571-7.
[http://dx.doi.org/10.1172/JCI0215217] [PMID: 11877463]
[36]
Ping W, Satoru N, Hong Y, et al. The susceptibility of T5-TG12 of the CFTR gene in chronic bronchitis occurrence in a Chinese population in Jiangsu province, China. J Biomed Res 2012; 26(6): 410-7.
[http://dx.doi.org/10.7555/JBR.26.20120015] [PMID: 23554779]
[37]
Aalbers BL, Yaakov Y, Derichs N, et al. Nasal potential difference in suspected cystic fibrosis patients with 5T polymorphism. J Cyst Fibros 2020; 19(4): 627-31.
[http://dx.doi.org/10.1016/j.jcf.2019.07.001] [PMID: 31331863]
[38]
Al-Shamrani A, Bagais K, Alenazi A, Alqwaiee M, Al-Harbi AS. Wheezing in children: Approaches to diagnosis and management. Int J Pediatr Adolesc Med 2019; 6(2): 68-73.
[http://dx.doi.org/10.1016/j.ijpam.2019.02.003] [PMID: 31388550]
[39]
Bongiovanni A, Manti S, Parisi GF, et al. Focus on gastroesophageal reflux disease in patients with cystic fibrosis. World J Gastroenterol 2020; 26(41): 6322-34.
[http://dx.doi.org/10.3748/wjg.v26.i41.6322] [PMID: 33244195]
[40]
Manti S, Parisi GF, Giacchi V, et al. Pilot study shows right ventricular diastolic function impairment in young children with obstructive respiratory disease. Acta Paediatr 2019; 108(4): 740-4.
[http://dx.doi.org/10.1111/apa.14574] [PMID: 30194783]
[41]
Manti S, Galdo F, Parisi GF, et al. Long-term effects of bronchopulmonary dysplasia on lung function: a pilot study in preschool children’s cohort. J Asthma 2021; 58(9): 1186-93.
[http://dx.doi.org/10.1080/02770903.2020.1779289] [PMID: 32508174]
[42]
Parisi GF, Manti S, Papale M, et al. Protracted bacterial bronchitis: More to know. J Biol Regul Homeost Agents 2022; 36(S1): 135-43.
[43]
Rock MJ, Levy H, Zaleski C, Farrell PM. Factors accounting for a missed diagnosis of cystic fibrosis after newborn screening. Pediatr Pulmonol 2011; 46(12): 1166-74.
[http://dx.doi.org/10.1002/ppul.21509] [PMID: 22081556]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy